June 30, 2024
March 25, 2024
March 25, 2024
This latest patent registration provides a pathway to commercial agreements in Canada with high economic potential for CureLab Oncology; separately, CureLab Oncology has provided exclusive licensing rights to its sister company, CureLab Veterinary, for use with dogs, cats and horses
CureLab Oncology Secures Patent Protection in Canada for Elenagen, Its P62 Plasmid Cancer Therapeutic
This latest patent registration provides a pathway to commercial agreements in Canada with high economic potential for CureLab Oncology; separately, CureLab Oncology has provided exclusive licensing rights to its sister company, CureLab Veterinary, for use with dogs, cats and horsesSeptember 29, 2023
September 29, 2023
CureLab Veterinary is aiming to commercialize a biologic that can alter the microenvironment of cancerous tumors in pets. S&P Global senior analyst Sian Lazell spoke to the company about its anti-cancer vaccine candidate and future pipeline targets.
(This article republished with the kind permission of S&P Global)
CureLab seeks new strategic partners to bring cancer innovation to market
CureLab Veterinary is aiming to commercialize a biologic that can alter the microenvironment of cancerous tumors in pets. S&P Global senior analyst Sian Lazell spoke to the company about its anti-cancer vaccine candidate and future pipeline targets.
(This article republished with the kind permission of S&P Global)July 16, 2023
